A Cross-Sectional Study of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Diabetes Mellitus: The TEMD Overtreatment Study.

Arterial blood pressure Glycemia Older adults Overtreatment Type 2 diabetes Undertreatment

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
05 2020
Historique:
received: 29 12 2019
pubmed: 24 2 2020
medline: 24 2 2020
entrez: 24 2 2020
Statut: ppublish

Résumé

Targeting better glycated hemoglobin (HbA1c) and blood pressure (BP) goals may endanger older adults with type 2 diabetes mellitus (T2DM). Overtreatment of T2DM and hypertension is a trending issue, although undertreatment is still common. We investigated the rates and predictors of overtreatment and undertreatment of glycemia and BP in older adults with T2DM and physicians' attitudes to deintensify or intensify treatment. Data from older adults (≥ 65 years) enrolled in a large nationwide T2DM survey in 2017 across Turkey were analyzed. Overtreatment of glycemia was defined as HbA1c < 6.5% plus the use of ≥ 2 oral antihyperglycemics or insulin, and BP overtreatment was defined as systolic BP (SBP) < 120 mmHg or diastolic BP (DBP) < 65 mmHg plus the use of ≥ 2 drugs. Undertreatment of glycemia was defined as HbA1c > 9%, and BP undertreatment was defined as SBP > 150 mmHg or DBP > 90 mmHg. Deintensification or intensification rates were calculated according to treatment modification initiated by the treating physician(s). The rate of overtreatment in the glycemia group (n = 1264) was 9.8% (n = 124) and that in the BP group (n = 1052) was 7.3% (n = 77), whereas the rate of undertreatment was 14.2% (n = 180) and 15.2% (n = 160), respectively. In the adjusted model, use of oral secretagogues (sulfonylureas or glinides) (odds ratio [OR] 1.94, 95% confidence interval [CI] 1.2-3.1) and follow-up at a private clinic (OR 1.81, 95% CI 1.0-3.3) were predictors of glycemia overtreatment. BP overtreatment was independently associated with the use insulin-based diabetes therapies (OR 1.86, 95% CI 1.14-3.04). There was no independent association of BP undertreatment to the study confounders. The deintensification and intensification rates were 25 and 75.6%, respectively, for glycemia and 10.9 and 9.2%, respectively, for BP. The results show that one in ten older adults with T2DM are overtreated while one in four require modification of their current antihyperglycemic and antihypertensive treatments. Physicians are eager to intensify medications while they largely ignore deintensification in diabetes management. These results warrant enforced measures to improve the care of older adults with T2DM. ClinicalTrials.gov identifier, NCT03455101. Type 2 diabetes mellitus (T2DM) is prevalent in the elderly population. Strict glycemia and blood pressure (BP) targets do not improve outcomes but they may increase the rate of adverse events in these patients. Consequently, overtreatment has been an emerging issue in recent years. The overall magnitude of the problem is largely unknown. Therefore, we assessed the rates and predictors of overtreatment and undertreatment of blood glucose and BP in Turkish older adults with T2DM. We also investigated physicians’ reactions to treatment modulation in the overtreated or undertreated patients. Patients participating in the study were: older adults (n = 1264) with T2DM from a cross-sectional, nationwide, multicenter study who followed-up at the same unit during the past 12 months and who did not have decompensated liver disease, psychiatric disorders interfering with cognition or compliance, bariatric surgery in the past 12 months or renal replacement therapy. We found that: • One of ten older adults with T2DM were overtreated for glycemia. • One in four older adults with T2DM required modification of antihyperglycemic treatment with inclusion of the number of insufficiently treated individuals. • One in four older adults with T2DM required modification of antihypertensive treatment. • Physicians are much more inclined to intensify antihyperglycemia medications, while they largely ignore the need for deintensification in the overtreated patients. • Physicians did not modify antihypertensive treatments in about 90% of patients with uncontrolled BP. • Patients who were treated by oral secretagogues and followed in private clinics were most prone to glycemia overtreatment. • Patients who were treated by insulin-based regiments were prone to BP overtreatment. These results suggest that measures should be taken to improve physician awareness of drug modification in older patients with T2DM.

Autres résumés

Type: plain-language-summary (eng)
Type 2 diabetes mellitus (T2DM) is prevalent in the elderly population. Strict glycemia and blood pressure (BP) targets do not improve outcomes but they may increase the rate of adverse events in these patients. Consequently, overtreatment has been an emerging issue in recent years. The overall magnitude of the problem is largely unknown. Therefore, we assessed the rates and predictors of overtreatment and undertreatment of blood glucose and BP in Turkish older adults with T2DM. We also investigated physicians’ reactions to treatment modulation in the overtreated or undertreated patients. Patients participating in the study were: older adults (n = 1264) with T2DM from a cross-sectional, nationwide, multicenter study who followed-up at the same unit during the past 12 months and who did not have decompensated liver disease, psychiatric disorders interfering with cognition or compliance, bariatric surgery in the past 12 months or renal replacement therapy. We found that:

Identifiants

pubmed: 32088879
doi: 10.1007/s13300-020-00779-0
pii: 10.1007/s13300-020-00779-0
pmc: PMC7193034
doi:

Banques de données

ClinicalTrials.gov
['NCT03455101']

Types de publication

Journal Article

Langues

eng

Pagination

1045-1059

Subventions

Organisme : Turkish Society of Endocrinology and Metabolsim
ID : 001
Pays : International

Investigateurs

Sibel Guldiken (S)
Semra Ayturk (S)
Murat Yilmaz (M)
Mehmet Asik (M)
Nevin Dinccag (N)
Ilhan Satman (I)
Ramazan Cakmak (R)
Fulya Turker (F)
Cemile Idiz (C)
Hulya Hacisahinogullari (H)
Elif Bagdemir (E)
Busra Yildiz (B)
Volkan Demirhan Yumuk (VD)
Ozlem Haliloglu (O)
Serpil Salman (S)
Seda Sancak (S)
Levent Ozsari (L)
Eylem Cagiltay (E)
Oguzhan Deyneli (O)
Eren Imre (E)
Sait Gonen (S)
S Nur Boysan (SN)
Yuksel Altuntas (Y)
Feyza Yener Ozturk (FY)
Meral Mert (M)
Hamide Piskinpasa (H)
Hasan Aydin (H)
Sazi Imamoglu (S)
Canan Ersoy (C)
Ozen Oz Gul (O)
Sinem Kucuksarac Kiyici (S)
Berrin Cetinarslan (B)
Alev Selek (A)
Teoman Dogru (T)
Ali Kirik (A)
Nur Kebapci (N)
Belgin Efe (B)
Ahmet Kaya (A)
Ilker Cordan (I)
Suleyman Baldane (S)
Cem Onur Kirac (CO)
Alper Sonmez (A)
Cem Haymana (C)
Ibrahim Demirci (I)
Zehra Capa (Z)
Cem Barcın (C)
Mustafa Cesur (M)
Ilhan Yetkin (I)
Demet Corapcioglu (D)
Sule Canlar (S)
Okan Bulent Yildiz (OB)
Suleyman Nahit Sendur (SN)
Bekir Cakir (B)
Didem Ozdemir (D)
Ahmet Corakci (A)
Mustafa Kutlu (M)
Neslihan Bascil Tutuncu (N)
Yusuf Bozkus (Y)
Erman Cakal (E)
Berrin Demirbas (B)
Sibel Ertek (S)
Mustafa Altay (M)
Murat Dagdeviren (M)
Oguzhan Sıtkı Dizdar (OS)
Fahri Bayram (F)
Amir Hassein Abedi (AH)
Sevki Cetinkalp (S)
Hatice Ozisik (H)
Guzide Gonca Oruk (GG)
Serkan Yener (S)
Basak Ozgen Saydam (BO)
Engin Guney (E)
Mustafa Unubol (M)
Guzin Fidan Yaylali (GF)
Senay Topsakal (S)
Zeliha Hekimsoy (Z)
Gulhan Akbaba (G)
Ibrahim Aslan (I)
Mustafa Kemal Balci (MK)
Sefika Dalkiran (S)
Esen Akbay (E)
Kamile Gul (K)
Eren Gurkan (E)
Kemal Agbaht (K)
Muge Ozsan Yilmaz (MO)
Emre Bozkirli (E)
B Tamer Tetiker (BT)
Seher Cetinkaya Altuntas (S)
Aysegul Atmaca (A)
Elif Tutku Durmus (ET)
Turkan Mete (T)
Faruk Kutluturk (F)
Ferit Kerim Kucukler (FK)
Oguz Dikbas (O)
Safak Akin (S)
Irfan Nuhoglu (I)
Halil Onder Ersoz (HO)
Taner Bayraktaroglu (T)
Ayse Kargılı Carlioglu (AK)
Pınar Sisman (P)
İbrahim Sahin (İ)
Sedat Cetin (S)
İlyas Capoglu (İ)
Emin Murat Akbas (EM)
Rıfkı Ucler (R)
Tevfik Sabuncu (T)
Mehmet Ali Eren (MA)
Alpaslan Kemal Tuzcu (AK)
Zafer Pekkolay (Z)
Mesut Ozkaya (M)
Mustafa Araz (M)

Commentaires et corrections

Type : CommentIn

Références

Patient Prefer Adherence. 2013;7:183-9
pubmed: 23487395
Diabetes Res Clin Pract. 2017 Jun;128:40-50
pubmed: 28437734
Diabetes Ther. 2013 Dec;4(2):175-94
pubmed: 23990497
Diabetologia. 2018 Dec;61(12):2461-2498
pubmed: 30288571
J Gerontol B Psychol Sci Soc Sci. 2010 May;65B(3):390-9
pubmed: 19541672
Cardiovasc Diabetol. 2018 Feb 12;17(1):27
pubmed: 29433515
Diabetes Care. 2019 Jan;42(Suppl 1):S90-S102
pubmed: 30559235
J Gen Intern Med. 2018 Jan;33(1):34-41
pubmed: 28905179
J Diabetes. 2017 Jan;9(1):76-84
pubmed: 26847713
JAMA Intern Med. 2015 Mar;175(3):356-62
pubmed: 25581565
BMJ Open Diabetes Res Care. 2017 Jan 17;5(1):e000297
pubmed: 28123754
Diabetes Res Clin Pract. 2018 Dec;146:138-147
pubmed: 30244051
N Engl J Med. 2010 Apr 29;362(17):1575-85
pubmed: 20228401
Turk Kardiyol Dern Ars. 2019 Sep;47(6):535-546
pubmed: 31483311
Diabetes Care. 2003 Mar;26(3):917-32
pubmed: 12610059
JAMA Intern Med. 2015 Dec;175(12):1942-9
pubmed: 26502220
Diabetes Care. 2019 Jan;42(Suppl 1):S139-S147
pubmed: 30559238
South Med J. 1985 Feb;78(2):162-6
pubmed: 3975712
BMC Geriatr. 2016 Mar 15;16:67
pubmed: 26979576
Ann Intern Med. 2006 Jun 20;144(12):884-93
pubmed: 16785477
N Engl J Med. 2008 Jun 12;358(24):2545-59
pubmed: 18539917
BMJ Open. 2014 Dec 08;4(12):e006544
pubmed: 25488097
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Evid Based Med. 2016 Aug;21(4):158
pubmed: 27388796
Ann Intern Med. 2009 Dec 15;151(12):854-60
pubmed: 20008761
J Am Geriatr Soc. 2013 Nov;61(11):2020-6
pubmed: 24219204
Diabetes Care. 2006 Nov;29(11):2415-9
pubmed: 17065677
Diabetes Care. 2017 Sep;40(9):1273-1284
pubmed: 28830958
Ann Fam Med. 2004 Sep-Oct;2(5):455-61
pubmed: 15506581
J Am Coll Cardiol. 2012 Aug 14;60(7):599-606
pubmed: 22796254
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27
pubmed: 29222373
Prim Care Diabetes. 2018 Apr;12(2):192-194
pubmed: 29396204
J Hum Hypertens. 2017 Aug;31(8):501-510
pubmed: 28230062
N Engl J Med. 2009 Jan 8;360(2):129-39
pubmed: 19092145
J Am Geriatr Soc. 2013 Apr;61(4):622-31
pubmed: 23469880
Am J Hypertens. 1996 May;9(5):419-25
pubmed: 8735171
J Clin Hypertens (Greenwich). 2014 Apr;16(4):270-6
pubmed: 24621268
Clin Ther. 2017 Apr;39(4):759-770
pubmed: 28342563
Diabetes Care. 2013 Mar;36(3):543-9
pubmed: 23193208
Drugs Aging. 2013 Oct;30(10):793-807
pubmed: 23912674
Diabetes Care. 2012 Dec;35(12):2533-9
pubmed: 22912429
JAMA Intern Med. 2014 Feb 1;174(2):259-68
pubmed: 24322626
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916

Auteurs

Alper Sonmez (A)

Department of Endocrinology and Metabolism, Gulhane School of Medicine, University of Health Sciences, Ankara, Turkey. alpersonmez@yahoo.com.

Ilker Tasci (I)

Department of Internal Medicine, Gulhane School of Medicine, University of Health Sciences, Ankara, Turkey.

Ibrahim Demirci (I)

Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.

Cem Haymana (C)

Department of Endocrinology and Metabolism, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.

Cem Barcin (C)

Department of Cardiology, Gulhane School of Medicine, University of Health Sciences, Ankara, Turkey.

Hasan Aydin (H)

Department of Endocrinology and Metabolism, School of Medicine, Yeditepe University, Istanbul, Turkey.

Sevki Cetinkalp (S)

Department of Endocrinology and Metabolism, School of Medicine, Ege University, Izmir, Turkey.

Feyza Yener Ozturk (FY)

Department of Endocrinology and Metabolism, Sisli Hamidiye Etfal Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.

Kamile Gul (K)

Department of Endocrinology and Metabolism, School of Medicine, Sutcu Imam University, Kahramanmaras, Turkey.

Tevfik Sabuncu (T)

Department of Endocrinology and Metabolism, School of Medicine, Harran University, Sanliurfa, Turkey.

Ilhan Satman (I)

Department of Endocrinology and Metabolism, School of Medicine, Istanbul University, Istanbul, Turkey.

Fahri Bayram (F)

Department of Endocrinology and Metabolism, School of Medicine, Erciyes University, Kayseri, Turkey.

Classifications MeSH